Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Phase 3CompletedNCT01764295

Daewoong Pharmaceutical Co. LTD.150 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of DWJ1276

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

150

Conditions

Hypertension Dyslipidemia

Interventions

DWJ1276DRUG

OlmesartanDRUG

RosuvastatinDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult male and female in between ages of 20 and 80 at the time of screening * Subject who can understand information provided and who can sign written consent voluntarily Exclusion Criteria: * Patients with hypersensitivity to olmesartan and rosuvastatin * Pregnant or lactating women and fertile women who is not using proper contraceptive method * Patient with history of drug or alcohol abuse

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

LDL-C percent change of DWJ1276 from baseline

Time frame: 8weeks

DBP change of DWJ1276 from baseline

Time frame: 8weeks

Secondary Outcomes

Proportion of subjects who reached LDL-C treatment goal defined by NCEP ATP III guideline

Time frame: 8weeks

Proportion of subjects who reached blood pressure treatment goal defined by JNC VII report

Time frame: 8weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.